Literature DB >> 21437728

Experimental chemotherapy in paracoccidioidomycosis using ruthenium NO donor.

Wander Rogério Pavanelli1, Jean Jerley Nogueira da Silva, Carolina Panis, Thiago Mattar Cunha, Ivete Conchon Costa, Maria Claudia Noronha Dutra de Menezes, Francisco José de Abreu Oliveira, Luiz Gonzaga de França Lopes, Rubens Cecchini, Fernando de Queiroz Cunha, Maria Angélica Ehara Watanabe, Eiko Nakagawa Itano.   

Abstract

Paracoccidioidomycosis (PCM) is a granulomatous disease caused by a dimorphic fungus, Paracoccidioides brasiliensis (Pb). To determine the influence of nitric oxide (NO) on this disease, we tested cis-[Ru(bpy)2(NO)SO3](PF6), ruthenium nitrosyl, which releases NO when activated by biological reducing agents, in BALB/c mice infected intravenously with Pb 18 isolate. In a previous study by our group, the fungicidal activity of ruthenium nitrosyl was evaluated in a mouse model of acute PCM, by measuring the immune cellular response (DTH), histopathological characteristics of the granulomatous lesions (and numbers), cytokines, and NO production. We found that cis-[Ru(bpy)2(NO)SO3](PF6)-treated mice were more resistant to infection, since they exhibited higher survival when compared with the control group. Furthermore, we observed a decreased influx of inflammatory cells in the lung and liver tissue of treated mice, possibly because of a minor reduction in fungal cell numbers. Moreover, an increased production of IL-10 and a decrease in TNF-α levels were detected in lung tissues of infected mice treated with cis-[Ru(bpy)2(NO)SO3](PF6). Immunohistochemistry showed that there was no difference in the number of VEGF- expressing cells. The animals treated with cis-[Ru(bpy)2(NO)SO3](PF6) showed high NO levels at 40 days after infection. These results show that NO is effectively involved in the mechanism that regulates the immune response in lung of Pb-infected mice. These data suggest that NO is a resistance factor during paracoccidioidomycosis by controlling fungal proliferation, influencing cytokine production, and consequently moderating the development of a strong inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21437728     DOI: 10.1007/s11046-011-9416-8

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  40 in total

Review 1.  Chemotherapy of Chagas' disease: status and new developments.

Authors:  Hugo Cerecetto; Mercedes González
Journal:  Curr Top Med Chem       Date:  2002-11       Impact factor: 3.295

2.  Immobilization of the [RuII(edta)NO+] Ion on the surface of functionalized silica gel.

Authors:  Patrícia G Zanichelli; Rosana L Sernaglia; Douglas W Franco
Journal:  Langmuir       Date:  2006-01-03       Impact factor: 3.882

3.  Trypanosoma cruzi: effect of the absence of 5-lipoxygenase (5-LO)-derived leukotrienes on levels of cytokines, nitric oxide and iNOS expression in cardiac tissue in the acute phase of infection in mice.

Authors:  Carolina Panis; Tânia Longo Mazzuco; Cauê Zortéa Fernandes Costa; Vanessa Jacob Victorino; Vera Lúcia Hideko Tatakihara; Lucy Megumi Yamauchi; Sueli Fumie Yamada-Ogatta; Rubens Cecchini; Luiz Vicente Rizzo; Phileno Pinge-Filho
Journal:  Exp Parasitol       Date:  2010-07-01       Impact factor: 2.011

4.  Antifungal type 1 responses are upregulated in IL-10-deficient mice.

Authors:  G Del Sero; A Mencacci; E Cenci; C F d'Ostiani; C Montagnoli; A Bacci; P Mosci; M Kopf; L Romani
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

5.  Dual role for nitric oxide in paracoccidioidomycosis: essential for resistance, but overproduction associated with susceptibility.

Authors:  Flávia R F Nascimento; Vera L G Calich; Dunia Rodríguez; Momtchilo Russo
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

6.  TNF-alpha-induced NF-kappaB signaling reverses age-related declines in VEGF induction and angiogenic activity in intervertebral disc tissues.

Authors:  Tetsuro Ohba; Hirotaka Haro; Takashi Ando; Masanori Wako; Fumiko Suenaga; Yoshinori Aso; Kensuke Koyama; Yoshiki Hamada; Atsuhito Nakao
Journal:  J Orthop Res       Date:  2009-02       Impact factor: 3.494

7.  Expression of inducible nitric oxide synthase by stimulated macrophages correlates with their antihistoplasma activity.

Authors:  T E Lane; G C Otero; B A Wu-Hsieh; D H Howard
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

8.  Experimental paracoccidioidomycosis: early immunosuppression occurs in susceptible mice after infection with pathogenic fungi.

Authors:  H C Teixeira; V L Calich; L M Singer-Vermes; M R D'Imperio-Lima; M Russo
Journal:  Braz J Med Biol Res       Date:  1987       Impact factor: 2.590

9.  Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase.

Authors:  J D MacMicking; C Nathan; G Hom; N Chartrain; D S Fletcher; M Trumbauer; K Stevens; Q W Xie; K Sokol; N Hutchinson
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

10.  In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors.

Authors:  J J N Silva; A L Osakabe; W R Pavanelli; J S Silva; D W Franco
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

View more
  6 in total

1.  The ruthenium nitric oxide donor, [Ru(HEDTA)NO], inhibits acute nociception in mice by modulating oxidative stress, cytokine production and activating the cGMP/PKG/ATP-sensitive potassium channel signaling pathway.

Authors:  Larissa Staurengo-Ferrari; Sandra S Mizokami; Victor Fattori; Jean J Silva; Patrícia G Zanichelli; Sandra R Georgetti; Marcela M Baracat; Luiz G da França; Wander R Pavanelli; Rubia Casagrande; Waldiceu A Verri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-13       Impact factor: 3.000

Review 2.  Animal Models and Antifungal Agents in Paracoccidioidomycosis: An Overview.

Authors:  Luciano Z Goldani; Fernanda Wirth
Journal:  Mycopathologia       Date:  2017-03-21       Impact factor: 2.574

3.  A divergent mode of activation of a nitrosyl iron complex with unusual antiangiogenic activity.

Authors:  Edinilton Muniz Carvalho; Lisa A Ridnour; Florêncio Sousa Gouveia Júnior; Pedro Henrique Bezerra Cabral; Nilberto Robson Falcão do Nascimento; David A Wink; Douglas W Franco; Mayara Jane Campos de Medeiros; Daniel de Lima Pontes; Elisane Longhinotti; Tércio de Freitas Paulo; Vania Bernardes-Génisson; Remi Chauvin; Eduardo Henrique Silva Sousa; Luiz Gonzaga de França Lopes
Journal:  J Inorg Biochem       Date:  2020-06-20       Impact factor: 4.155

4.  Nitric oxide and Brazilian propolis combined accelerates tissue repair by modulating cell migration, cytokine production and collagen deposition in experimental leishmaniasis.

Authors:  Milena Menegazzo Miranda; Carolina Panis; Allan Henrique Depieri Cataneo; Suelen Santos da Silva; Natalia Yoshie Kawakami; Luiz Gonzaga de França Lopes; Alexandre Tadachi Morey; Lucy Megumi Yamauchi; Célia Guadalupe Tardelli de Jesus Andrade; Rubens Cecchini; Jean Jerley Nogueira da Silva; José Maurício Sforcin; Ivete Conchon-Costa; Wander Rogério Pavanelli
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

5.  Antileishmanial Activity and Inducible Nitric Oxide Synthase Activation by RuNO Complex.

Authors:  Tatiane Marcusso Orsini; Natalia Yoshie Kawakami; Carolina Panis; Ana Paula Fortes Dos Santos Thomazelli; Fernanda Tomiotto-Pellissier; Allan Henrique Depieri Cataneo; Danielle Kian; Lucy Megumi Yamauchi; Florêncio S Gouveia Júnior; Luiz Gonzaga de França Lopes; Rubens Cecchini; Idessânia Nazareth Costa; Jean Jerley Nogueira da Silva; Ivete Conchon-Costa; Wander Rogério Pavanelli
Journal:  Mediators Inflamm       Date:  2016-10-04       Impact factor: 4.711

6.  Thiol-Activated HNO Release from a Ruthenium Antiangiogenesis Complex and HIF-1α Inhibition for Cancer Therapy.

Authors:  Eduardo Henrique Silva Sousa; Lisa A Ridnour; Florêncio S Gouveia; Carlos Daniel Silva da Silva; David A Wink; Luiz Gonzaga de França Lopes; Peter J Sadler
Journal:  ACS Chem Biol       Date:  2016-05-31       Impact factor: 5.100

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.